Advertisement

Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats

  • 27 Accesses

Abstract

The present study aims to discuss the effect of escitalopram in glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) levels, and 5-Hydroxytryptamine (5-HT) in obsessive–compulsive disorder rats. A total of 42 rats were divided into three groups randomly: control group (n = 14), model group (n = 14) (obsessive–compulsive disorder group), and escitalopram group (n = 14) (model + obsessive–compulsive disorder group + escitalopram treatment). The open-field method was used to test the rat behavior, enzyme-linked immunosorbent assay (ELISA) was used to determine the serum GDNF and BDNF levels. In addition, Western blot was used to determine the brain tissue protein levels of GDNF and BDNF and high-performance liquid chromatography + electrochemistry method to determine the 5-HT level of brain tissue. Visiting place was changed, rotational frequency and fixed duration enhanced in escitalopram group compared to model group (P < 0.05). Besides, GDNF and BDNF levels of serum and brain tissue were decreased in model group and escitalopram group compared to control group (P < 0.05), while GDNF and BDNF levels of serum and brain tissue were increased in escitalopram group compared to model group (P < 0.05). Moreover, the 5-HT level of brain tissue in escitalopram group was higher than that in model group (P < 0.05). Escitalopram could increase GDNF and BDNF levels and 5-HT content in serum and brain tissue in obsessive–compulsive disorder rats, which contributes to a function on the treatment of obsessive–compulsive disorder.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 199

This is the net price. Taxes to be calculated in checkout.

Fig. 1

References

  1. Bagheri A, Talei S, Hassanzadeh N, Mokhtari T, Akbari M, Malek F, Jameie SB, Sadeghi Y, Hassanzadeh G (2017) The neuroprotective effects of flaxseed oil supplementation on functional motor recovery in a model of ischemic brain stroke: upregulation of BDNF and GDNF. Acta Med Iran 55(12):785–792

  2. Bergman J, Pashinian A, Weizman A, Poyurovsky M (2014) The beneficial effect of escitalopram on obsessive-compulsive-related musical hallucinations in elderly patients with hearing impairment: a case series. Int Clin Psychopharmacol 29(5):263–265

  3. Çolak Sivri R, Bilgiç A, Kılınç İ (2018) Cytokine, chemokine and BDNF levels in medication-free pediatric patients with obsessive-compulsive disorder. Eur Child Adolesc Psychiatry 27(8):977–984

  4. de Wolmarans W, Brand L, Stein DJ, Harvey BH (2013) Reappraisal of spontaneous stereotypy in the deer mouse as an animal model of obsessive-compulsive disorder (OCD): response to escitalopram treatment and basal serotonin transporter (SERT) density. Behav Brain Res 256:545–553

  5. Eilam D, Golani I, Szechtman H (1989) D2-agonist quinpirole induces perseveration of routes and hyperactivity but no perseveration of movements. Brain Res 490(2):255–267

  6. Fontenelle LF, Barbosa IG, Luna JV, Rocha NP, Silva Miranda A, Teixeira AL (2012) Neurotrophic factors in obsessive-compulsive disorder. Psychiatry Res 199(3):195–200

  7. Ghio L, Gotelli S, Cervetti A, Respino M, Natta W, Marcenaro M, Serafini G, Vaggi M, Amore M, Belvederi Murri M (2015) Duration of untreated depression influences clinical outcomes and disability. J Affect Disord 175:224–228

  8. Goodman WK, Grice DE, Lapidus KA, Coffey BJ (2014) Obsessive-compulsive disorder. Psychiatr Clin North Am 37(3):257–267

  9. Guo Y, Luo C, Tu G, Li C, Liu Y, Liu W, Lam Yung KK, Mo Z (2018) Rhynchophylline downregulates phosphorylated cAMP response element binding protein, nuclear receptor-related-1, and brain-derived neurotrophic factor expression in the hippocampus of ketamine-induced conditioned place preference rats. Pharmacogn Mag 14(53):81–86

  10. Ho EV, Thompson SL, Katzka WR, Sharifi MF, Knowles JA, Dulawa SC (2016) Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation. Psychopharmacology 233(1):57–70

  11. Hou YC, Lai CH (2014) Rapid responses of high-dose combined therapy of escitalopram and aripiprazole in a case of severe obsessive compulsive disorder with delusion. J Neuropsychiatry Clin Neurosci 26(2):E44–E45

  12. Lee J, Kim BH, Kim E, Howes OD, Cho KIK, Yoon YB (2018) Kwon JS (2018) Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [11 C] DASB PET study. Hum Psychopharmacol 33(1):1–2. https://doi.org/10.1002/hup.2642

  13. Lochner C, Simmons C, Kidd M, Chamberlain SR, Fineberg NA, van Honk J, Ipser J, Stein DJ (2012) Differential effects of escitalopram challenge on disgust processing in obsessive-compulsive disorder. Behav Brain Res 226(1):274–280

  14. Marie C, Pedard M, Quirié A, Tessier A, Garnier P, Totoson P, Demougeot C (2018) Brain-derived neurotrophic factor secreted by the cerebral endothelium: a new actor of brainfunction? J Cereb Blood Flow Metab. 38(6):935–949

  15. Mori A, Nishioka Y, Yamada M, Nishibata Y, Masuda S, Tomaru U, Honma N, Moriyama T, Ishizu A (2018) Brain-derived neurotrophic factor induces angiogenin secretion and nuclear translocation in human umbilical vein endothelial cells. Pathol Res Pract 214(4):521–526

  16. Nakao T, Okada K, Kanba S (2014) Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings. Psychiatry Clin Neurosci 68(8):587–605

  17. Pedrotti Moreira F, Wiener CD, Jansen K, Portela LV, Lara DR, Souza LDM, da Silva RA, Oses JP (2018) Serum GDNF levels and anxiety disorders in a population-based study of young adults. Clin Chim Acta 485:21–25

  18. Pizarro M, Fontenelle LF, Paravidino DC, Yücel M, Miguel EC, de Menezes GB (2014) An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder. Expert Opin Pharmacother 15(10):1391–1401

  19. Ruven C, Badea SR, Wong WM, Wu W (2018) Combination treatment with exogenous GDNF and fetal spinal cord cells results in better motoneuron survival and functional recovery after avulsion injury with delayed root reimplantation. J Neuropathol Exp Neurol 77(4):325–343

  20. Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, Spivak B (2013) Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Int Clin Psychopharmacol 28(2):96–98

  21. Suliman S, Hemmings SM, Seedat S (2013) Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: systematic review and meta-regression analysis. Front Integr Neurosci 29(7):55

  22. Szechtman H, Sulis W, Eilam D (1998) Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112(6):1475–1485

  23. Wang X, Min S, Xie F, Yang J, Li L, Chen J (2018) Glial cell-derived neurotrophic factor alleviates sepsis-induced neuromuscular dysfunction by decreasing the expression of γ- and α7-nicotinic acetylcholine receptors in an experimental rat model of neuromyopathy. Biochem Biophys Res Commun 496(2):260–266

  24. Yan XP, Rao Y (2017) Comparison of the efficacy of escitalopram and paroxetine in the treatment of obsessive-compulsive disorder. Shanghai Med Pharmaceutical J 38(18):22–24

  25. Zhao LL (2016) Analysis of the efficacy and adverse reactions of escitalopram and paroxetine in the treatment of obsessive-compulsive disorder. Chin J Pract Nervous Dis 19(17):126–128

Download references

Acknowledgements

The research was funded from Henan science and technology department project (172102310578): Study of diffusion tensor imaging of white matter in patients with obsessive–compulsive disorder.

Author information

HRG and YMR was responsible for the study design and manuscript writing. BLH, YLW, and YYZ were responsible for the study execution and data collection. QGM and PPL were responsible for data management, data analysis, and interpretation. All the authors read and approved the final manuscript.

Correspondence to Hui-Rong Guo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guo, H., Huang, B., Wang, Y. et al. Effect of Escitalopram on Serum GDNF and BDNF Levels and 5-HT Level of Brain Tissue of Obsessive–Compulsive Disorder Rats. Cell Mol Neurobiol (2020) doi:10.1007/s10571-020-00788-4

Download citation

Keywords

  • Escitalopram
  • Obsessive–compulsive disorder
  • Glial cell-derived neurotrophic factor
  • Brain-derived neurotrophic factor
  • Serotonin